Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Thoracic 1Sarcoma 1Other solid neoplasm 1CNS 1

Conditions

Breast Neoplasms 17Ovarian Neoplasms 16Fallopian Tube Neoplasms 12Neoplasm Metastasis 10Triple Negative Breast Neoplasms 7Prostatic Neoplasms 7Neoplasms 7Endometrial Neoplasms 6Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neuroendocrine Tumors 3Metastatic Castration-resistant Prostate Cancer 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Sarcoma 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Osteosarcoma 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2

Interventions

lutetium Lu 177 dotatate 12Specimen Handling 6Magnetic Resonance Spectroscopy 6cabozantinib 5Everolimus 5pembrolizumab 4Nivolumab 4olaparib 3lenvatinib 3Cyclophosphamide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3lanreotide 2gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Phantoms, Imaging 2Octreotide 2Lutetium-177 2Ipilimumab 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2tivozanib 1surufatinib 1repotrectinib 1peposertib 1pazopanib 1entrectinib 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × olaparib × 90 days × Clear all
NCT06607692 2026-06-04

LUPARPED

Fundación de investigación HM

Phase 1/2 Recruiting
25 enrolled
CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT04375267 2026-04-14

LuPARP

Vastra Gotaland Region

Phase 1 Completed
18 enrolled
EndocrineNETOther solid neoplasmThoracic

Mesothelioma, Thymoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡